Litigation Details for Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals Inc. (D. Del. 2009)

« Back to Dashboard

Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals Inc. (D. Del. 2009)

Docket		Date Filed	2009-08-28
Court	District Court, D. Delaware	Date Terminated	2013-11-05
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	MATRIX LABORATORIES INC.
Patents	6,639,071; 6,939,964
Attorneys	Mary B. Graham
Firms	Buchanan Ingersoll & Rooney PC
Link to Docket	External link to docket

Details for Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals Inc. (D. Del. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-08-28				External link to document

Litigation summary and analysis for: Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals Inc. (D. Del. 2009)

Last updated: July 22, 2026

Bristol-Myers Squibb v. Mylan (1:09-cv-00651): Litigation Summary, Patent Issues, and Generic Entry Risk Analysis

Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals Inc., 1:09-cv-00651, is a Hatch-Waxman patent litigation in which BMS alleged that Mylan’s ANDA would infringe listed patents covering a BMS small-molecule product. The case is tied to an asserted Orange Book patent estate and typically frames the infringement/validity issues through Markman claim construction, infringement contentions, and Paragraph IV defenses. Without the docket document set and the asserted patent list, a complete, accurate litigation summary (claims at issue, asserted patents, infringement theories, and dispositive outcomes) cannot be produced.

What patents were asserted in Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals Inc. 1:09-cv-00651?

A litigation summary requires the specific Orange Book patents asserted in the complaint and any amended asserted-patent list, including:

• Patent numbers and titles
• Claims asserted (which claim numbers, independent vs dependent)
• Priority/filing dates and remaining term as of the filing year
• Whether any additional patents were asserted via amended pleadings

A correct answer depends on docket exhibits (complaint, amended complaints, infringement contentions, and scheduling orders) and the Orange Book listing for the ANDA submission identified in the case.

Which Orange Book-listed patents drive the infringement and validity disputes?

In Hatch-Waxman actions, asserted patents usually map to one of these buckets:

• Composition-of-matter (drug substance)
• Formulation (e.g., specific excipients, solid state, particle size, polymorph)
• Method-of-use (clinical regimen claims)
• Manufacturing process (process or intermediates)

A patent-by-patent analysis also depends on the claim construction record and final rulings.

How did BMS accuse Mylan’s ANDA product of infringement in 1:09-cv-00651?

A complete infringement analysis requires:

• The asserted patent claims and the specific product features alleged to meet claim limitations
• The technical expert positions for both sides
• The ANDA paragraph reference (e.g., Paragraph II/III/IV to specific patents)
• The “derived” product profile (strength, dosage form, formulation characteristics, release characteristics if relevant)

Without the infringement contentions and claim charts filed in the case, infringement cannot be summarized accurately.

What claim-construction and claim-chart issues typically decide these cases?

In BMS v. Mylan-style disputes, the outcome often turns on:

• Construction of key terms tied to the claimed composition/formulation parameters
• Whether Mylan’s proposed formulation falls within ranges or structural limitations
• Whether alleged differences are material or are dismissed as non-limiting

What defenses did Mylan raise in 1:09-cv-00651 (invalidity, unenforceability, non-infringement)?

A litigation summary should identify, by name:

• Invalidity grounds (anticipation/obviousness categories, printed publications, prior use/sale)
• Indefiniteness or lack of written description/enablement arguments
• Inequitable conduct or prosecution-history estoppel (if pleaded)
• Non-infringement positions (technology carve-outs, claim-limit mismatches)

These must be traced to the pleadings and claim construction/summary judgment papers.

Did the case involve venue/standing/ANDA-specific procedural motions?

Many ANDA cases include dispositive procedural disputes, such as:

• Venue challenges
• Failure-to-state-claim arguments tied to ANDA paragraph scope
• Stipulations regarding the ANDA product profile

Accurate reporting depends on the docket motion history.

When did exclusivity and patent term control generic entry exposure in this case?

For business planning, the relevant dates are:

• Asserted patent expiration dates (and any terminal disclaimers)
• Any pediatric exclusivity extensions (if applicable)
• Any FDA exclusivity periods for the drug product (NEYM, 505(b)(1), or first-approval exclusivity)
• Likely “final barrier” date if litigation stays are triggered by 505(j)(5)(B) proceedings

A correct timeline requires:

• The drug and the Orange Book listing for the ANDA
• The patent expiration and exclusivity calculations at the time of suit

Without the drug identity and asserted patent list from docket filings, an exclusivity timeline cannot be stated correctly.

What was the litigation outcome in 1:09-cv-00651 (dismissal, settlement, trial, judgment)?

A litigation summary must state:

• Final disposition (dismissed with/without prejudice, summary judgment, bench/jury judgment)
• Whether any preliminary injunction issued (rare in Hatch-Waxman unless at stake)
• Whether a settlement included:
  • Non-infringement admissions or covenant not to sue scope
  • Launch date commitments
  • Compulsory patent licensing terms
  • Fallback design-around commitments (if disclosed)

This information is contained in final orders, settlement filings, and consent judgments. It is not available in the prompt.

Did BMS and Mylan enter a settlement agreement, and what were the launch terms?

Settlement terms drive market exposure and follow-on Paragraph IV risk for other applicants. Typical settlement disclosures cover:

• Date of generic market entry
• Stipulated judgment designations
• Dismissal with prejudice timelines

Accurate reporting requires the settlement agreement or docket-linked order.

What is the Orange Book status of the patents at issue in 1:09-cv-00651?

Orange Book status analysis requires:

• The NDA and drug product for the litigation
• Patent listing details:
  • Regulatory listing type (drug substance vs drug product vs method)
  • Patent expiry
  • FDA approval history (including application type and exclusivity codes)
• Whether any patents were listed as “approved for” the ANDA versus listed only for reference

Without the NDA/product identifier tied to 1:09-cv-00651, the Orange Book cannot be mapped correctly.

How strong was the BMS patent estate versus Mylan’s ANDA launch risk?

A “strength” score needs:

• Which patents were asserted (method/formulation often weaker vs composition, but depends)
• Known claim-construction outcomes in the docket
• Whether the case proceeded to summary judgment or trial
• Litigation history for the same patents across other ANDA filers

Without asserted patent identity, the strength analysis would be speculative.

How does this case compare with other BMS v. ANDA litigations over the same patent family?

A comparison requires:

• Other cases involving the same Orange Book patents
• Whether courts sustained or invalidated similar claims
• Whether settlements cluster around the same launch windows

That cross-case mapping depends on the asserted patent list.

Which generic entry scenarios were realistically blocked by the asserted patents?

Generic entry planning in Hatch-Waxman typically branches by:

• Switching from infringement to design-around formulation (if formulation patents)
• Waiting out method-of-use patents vs launching composition claims
• Carving out specific strengths or dosage forms if only some were asserted

A correct entry scenario requires:

• The dosage form and strength(s) at issue
• The asserted claim scope (global vs strength-specific)
• The settlement or judgment scope

What manufacturing and IP barriers would affect Mylan if the case had proceeded to infringement/validity rulings?

If formulation or process patents were asserted, barriers may include:

• Locked excipient compositions or specified particle size/polymorph requirements
• Process steps tied to intermediates or crystallization conditions
• Stability, bioavailability, and dissolution targets required to support FDA approval

These determinations require the infringement contentions and the expert report record.

Key Takeaways

• 1:09-cv-00651 is a Hatch-Waxman patent litigation, but the prompt does not provide the drug identity, asserted patent numbers, or docket outcome.
• A litigation summary that supports licensing, investment, or R&D decisions requires the complaint/amended complaint asserted-patent list and the final disposition or settlement order.
• Without those docket facts, any statement about infringed claims, invalidity grounds, settlement terms, or launch dates would be non-actionable.

FAQs

1. What does a BMS v. Mylan “Paragraph IV” filing typically allege in ANDA litigation?
2. How are formulation and method-of-use patents analyzed differently from composition-of-matter in Hatch-Waxman cases?
3. What documents on a federal docket usually contain the operative asserted-patent list in ANDA litigation?
4. How do settlement “covenant not to sue” clauses affect downstream generic competitors?
5. What court filings determine whether a generic’s design-around avoids infringement?

References

1. Federal court docket for Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals Inc., No. 1:09-cv-00651 (access to PACER/docket required).